MedTrace Logo

The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer

NCT01331525 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2016-04-14

No results posted yet for this study

Summary

This trial will investigate the addition of an antibody (Ipilimumab) to conventional Carboplatin and Etoposide chemotherapy in extensive stage small cell lung cancer.

The primary objective is to establish the progression free survival at 1 year.

Conditions

Interventions

BIOLOGICAL

Ipilimumab

This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • Institute of Cancer Research, United Kingdom

    collaborator OTHER

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Christian H Ottensmeier, MD, PhD · University Hospital Southampton NHS Foundation Trust

  • Matthew Wheater, MD · University Hospital Southampton NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01331525 on ClinicalTrials.gov